The CTMM Portfolio

Public-private partnerships to develop innovative medical technologies


Cancer, cardiovascular, neurodegenerative, infectious, and autoimmune diseases are among the leading causes of disease burden for patients and society. The Center for Translational Molecular Medicine (CTMM) was established in 2008 to address these areas, supported by FES funding (Dutch natural gas reserve fund).

icon_Money €321 M

allocated budget

icon_Hands 133


About the CTMM Portfolio

CTMM was set up to help drive the development of molecular diagnostics and molecular imaging technologies, focusing on translational aspects of molecular medicine. The goal was to ensure that scientific results can be applied as quickly as possible in patient care – with earlier and more precise diagnosis of disease, and the design of highly personalized therapies.

All Dutch university medical centers, several universities, and more than 90 companies were involved in a wide range of CTMM research projects. These projects combined R&D, clinical resources, and research infrastructure so that patients with complex diseases could benefit from innovative treatments. A strong translational focus was reflected by financial support for the projects from six Dutch health foundations. In all, CTMM had 133 partners, with €321 million in allocated budget until the end of 2015, and was part of 32 projects/consortia.

Examples of CTMM consortia and their outputs include:

  • Translational Research IT (TraIT): sustainable infrastructure for biomedical research (download pdf, output dated 31 December 2016. Tools and services developed in TraIT are continued within Health-RI)
  • PREDICCT: early diagnoses and treatment of diabetes (download pdf in Englishdownload pdf in Dutch)
  • Breast CARE: predicting therapy response in breast cancer patients (download pdf)
  • Circulating Cells: investigation of 'circulating cells' (e.g. white blood cells and platelets) to see if they carry biomarkers suitable for identifying patients with an increased risk of developing unstable plaques (download pdf in Englishdownload pdf in Dutch)
  • LeARN: development and evaluation of tools for an earlier and more reliable diagnosis of Alzheimer’s Disease (download pdf)
  • Patient Involvement for Translational Research: A step-by-step patient involvement guide that can be used during current projects or when preparing future project proposals (in Dutch) (download pdf) and a method to help patients have their say (in Dutch) (download pdf
  • Medical Technology Assessment (MTA): sustainable, accessible and high-quality powerful tools to provide necessary decision support during process of translational research (download pdf)

Translating science into better healthcare

Program management and scientific expertise 
CTMM was an independent partner – able to balance the many competing priorities within a large public-private partnership. Team members have PhD degrees and experience within industrial settings, ensuring academic and commercial credibility. This means they can help to guide projects towards delivering the best achievable combination of real-world clinical applications and commercial returns, along with journal publications and post-doc/ PhD opportunities.

Research infrastructure
Solutions developed during the course of the CTMM program have also been turned into generic translational research infrastructure. The TraIT project is one example, providing a research IT infrastructure capable of collecting, storing, analyzing, archiving, and securing the vast data volumes generated during operational medical research projects.

By merging with TI Pharma to form Lygature, CTMM became part of an organization capable of addressing major challenges within medical technology and pharmacotherapy. Lygature brings together public and private partners, and creates solutions that exploit molecular diagnostics and molecular imaging as well as drug development.

Project updates

  • Medical innovation: CTMM and TI Pharma join forces

    Leading Dutch technology institutes CTMM (Center for Translational Molecular Medicine) and TI Pharma have joined forces, in a merger that addresses the growing interdependence of medicines and medical technology.